Skip to main content
OpenTrials
Completed

NCT Number: NCT04213885

Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position

To determine whether the Peschke PXL-330 is safe and effective in the treatment of corneal thinning conditions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Eye Specialists of Indiana

Indianapolis, Indiana, 46220, United States

About this study

Patients with progressive keratoconus, pellucid marginal degeneration, infectious keratitis, or at risk for post-refractive corneal ectasia will be recruited and undergo epithelial-on corneal crosslinking with the Peschke PXL-330 system using pulsed, accelerated energy delivery. Patients will undergo monitoring for 1 year, with serial measurements of corneal topography, visual acuity, intraocular pressure and visual function questionnaire.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Criterion 1,2,3 are required for all participants. Participants must also meet one or more of criteria 4-12. Criteria 13 is only relevant for contact lens wearers.

  • 12 years of age or older
  • Signed written informed consent
  • Willingness and ability to comply with schedule for follow-up visits
  • Presence of central or inferior steepening
  • Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid marginal degeneration
  • Presence of one or more findings associated with keratoconus or pellucid marginal degeneration, such as
  • Fleisher ring
  • Vogt's striae
  • Decentered corneal apex
  • Munson's sign
  • Rizzutti's sign
  • Apical corneal scarring consistent with Bowman's breaks
  • Scissoring of the retinoscopic reflex
  • Crab-claw appearance on topography
  • Steepest keratometry (Kmax) value greater than or equal to 47.2
  • I-S keratometry difference < 1.5 D on the Pentacam map or topography map
  • Posterior corneal elevation > 16 microns
  • Thinnest corneal point <485 microns
  • Predicted Post LASIK/PRK stromal ablation depth <350 microns or expected keratometry >47.2, or patients undergoing PRK/SMILE in keratoconus suspect eyes
  • Bacterial or fungal keratitis persistent and not responding despite > 2 weeks of standard antimicrobial therapy or with rapid progression of corneal thinning, with loss of >25% corneal thickness
  • Contact lens wearers only:
  • Removal of contact lenses for the require period of time prior to the screening refraction:

Contact Lens Type Discontinuations Time: Soft, 1 week; Soft Extended Wear, 2 weeks; Soft Toric, 3 weeks; Rigid Gas Permeable, 2 weeks per decade of wear -

Exclusion criteria

  • Eyes classified as normal or atypical normal on the severity grading scheme
  • Corneal pachymetry at the screening exam that is <300 microns at the the thinnest point in the eye(s) to be treated.
  • Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye for future complications, for example:
  • History of or active corneal disease (e.g. herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, acanthamoeba, etc.)
  • Clinically significant corneal scarring the CXL treatment zone that is not related to keratoconus or, in the investigator's opinion, will interfere with the cross-linking procedure.
  • Pregnancy (including plan to become pregnant) or lactation during the course of the study
  • A known sensitivity to the study medications
  • Patients with nystagmus or any other condition that would prevent a steady gaze during the CXL treatment of diagnostic tests.
  • Patients with a current condition that, in the physician's opinion, wold interfere with or prolong epithelial healing.

-

Treatment and study plan

PXL 330 Platinum device/Riboflavin

Combination Product

30mW, 5 sec, 5 sec off, 10 minutes of illumination

Primary outcomes

  1. Mean keratometry in diopters

    Time frame: 1 year

    Average keratometry across the anterior topography of the cornea computed by a validated Scheimpflug topographer

Secondary outcomes

  1. Best corrected visual acuity

    Time frame: 1 year

    Measurement of best corrected visual acuity on the validated early-treatment diabetic retinopathy study scale

Sponsors and collaborators

Lead sponsor

Eye Specialists of Indiana

Other

Registry information

Official study title

Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking With Corneal Thinning Conditions

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Dec 30, 2019
Registry last updated
Aug 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.